Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143973 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
A Phase 2 study, sponsored by Trevi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT02143973: Completed Phase 2 study, sponsored by Trevi Therapeutics.
NCT02143973 is a Phase 2 study that has completed, run by Trevi Therapeutics. The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02143973, a Phase 2 study, has completed, sponsored by Trevi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
Primary Outcome
The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)
Interventions
- DRUG nalbuphine HCl ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02143973 record still lists
NCT02143973 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 1 intervention - of which nalbuphine HCl ER is the first listed.
NCT02143973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02143973 about?
NCT02143973 is a clinical study titled "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus". The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
What is the current status of trial NCT02143973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2014-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02143973?
The interventions under investigation include: nalbuphine HCl ER (DRUG).
Who is sponsoring clinical trial NCT02143973?
This trial is sponsored by Trevi Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02143973's enrollment target sits among peer trials
167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia